Monday, January 22, 2018
 
 
AssureCare® and Kroger Achieve Level III (Active Medication) Capability for the Pharmacist Electronic Care Plan (eCare Plan)
CINCINNATI, Jan. 22, 2018 /PRNewswire/ -- AssureCare and Kroger today announced that they achieved Level III capability from Community Care of North Carolina (CCNC) for the Pharmacist eCare Plan initiative. Using AssureCare's solution, MedCompass, Kroger pharmacies in
 



The global intraocular lenses (IOLs) market is expected to reach USD 5.54 billion by 2025
LONDON, Jan. 22, 2018 /PRNewswire/ -- Intraocular Lens (IOL) Market Analysis By Product (Monofocal, Multifocal, Toric, and Accommodative), By End User, By Region, And Segment Forecasts, 2014 - 2025

Download the full report: https://.....
 
Inspirational True Story of Learning to Heal

PLACENTIA, Calif. (PRWEB) January 22, 2018

 
The global ambulance services market is anticipated to reach USD 48.9 billion by 2025
NEW YORK, Jan. 22, 2018 /PRNewswire/ -- Ambulance Services Market Analysis by Transport Vehicle (Ground, Air, Water), by Emergency Services (Emergency & Non-Emergency), by Equipment (Advance & Basic Life Support (ALS & BLS)), and Segment Forecasts, 2014 - 2025

Read the full report:
 
Centene Awarded Statewide Medicaid Contract In New Mexico
ST. LOUIS, Jan. 22, 2018 /PRNewswire/ -- Centene Corporation (NYSE: CNC) announced today that its New Mexico subsidiary, Western Sky Community Care, has been awarded a statewide contract in New Mexico for the Centennial Care 2.0 Program. The new five-year contract is effective on
 
Klogene and Boston University Scientists are First to use CRISPR for Activation of the Life Extension and Cognition Enhancing Klotho Gene
BOSTON, Jan. 22, 2018 /PRNewswire/ -- In a paper published today in Journal of Molecular Neuroscience, scientists from Klogene Therapeutics, Inc. and Boston University School of Medicine showed efficient transcriptional activation of the anti-aging multifunctional gene Klotho by CRISPR-dCas9.
 
Regeneron Announces Approval of DUPIXENT® (dupilumab) in Japan for the Treatment of Atopic Dermatitis
TARRYTOWN, N.Y., Jan. 22, 2018 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the Ministry of Health, Labor and Welfare (MHLW) in Japan has granted marketing and manufacturing authorization for DUPIXENT® (dupilumab) for the treatment of at.....
 


 
 
 
 
 
 
 
 
 
 
 
 
 





About The Health Technology - Contact Us - Advertise With Us - Privacy Guidelines